אקסמסטאן טבע  25 מג ישראל - עברית - Ministry of Health

אקסמסטאן טבע 25 מג

abic marketing ltd, israel - exemestane - טבליות מצופות פילם - exemestane 25 mg - exemestane

נורופן קפסולות נוזל 200 מג ישראל - עברית - Ministry of Health

נורופן קפסולות נוזל 200 מג

reckitt benckiser (near east) ltd - ibuprofen - קפסולות ממולאות נוזל - ibuprofen 200 mg - ibuprofen - ibuprofen - relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic diseases, reduction of fever.

נורופן קוויק 256 מג ישראל - עברית - Ministry of Health

נורופן קוויק 256 מג

reckitt benckiser (near east) ltd - ibuprofen sodium dihydrate - טבליה - ibuprofen sodium dihydrate 256 mg - ibuprofen - ibuprofen - for the symptomatic relief of mild to moderate pain, such as hedache, backache, period pain, dental pain, neuralgia, rheumatic and muscular pain, the pain of non-serious arthritis, migraine, cold and flu symptoms, sore throat and fever.

נורופן קוויק 512 מג ישראל - עברית - Ministry of Health

נורופן קוויק 512 מג

reckitt benckiser (near east) ltd - ibuprofen sodium - טבליה - ibuprofen sodium 512 mg - ibuprofen - ibuprofen - for the symptomatic relief of mild to moderate pain, such as hedache, backache, period pain, dental pain, neuralgia, rheumatic and muscular pain, the pain of non-serious arthritis, migraine, cold and flu symptoms, sore throat and fever.

לוסנטיס ישראל - עברית - Ministry of Health

לוסנטיס

novartis israel ltd - ranibizumab - תמיסה להזרקה - ranibizumab 10 mg/ml - ranibizumab - ranibizumab - treatment of patients with neovascular (wet) age-related macular degeneration (amd).treatment of adult patients with visual impairment due to diabetic macular oedema (dme) .the treatment of visual impairement due to macular oedema secondary to retinal vein occulsion (rvo).the treatment of visual impaiment due to choroidal neovacularization (cnv) secondary to pathologic myopia (pm).

נבנק ישראל - עברית - Ministry of Health

נבנק

novartis israel ltd - nepafenac - תרחיף לעין - nepafenac 0.1 % - nepafenac - nepafenac - prevention and treatment of postoperative pain and inflammation associated with cataract surgery and reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

אזרגה ישראל - עברית - Ministry of Health

אזרגה

novartis israel ltd - brinzolamide; timolol as maleate - תרחיף לעין - brinzolamide 10 mg/ml; timolol as maleate 5 mg/ml - timolol, combinations - timolol, combinations - decrease of intra-ocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

אנסטרוז ישראל - עברית - Ministry of Health

אנסטרוז

taro international ltd - anastrozole 1 mg - tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

אנסטרוזול מדיטק 1 מ"ג ישראל - עברית - Ministry of Health

אנסטרוזול מדיטק 1 מ"ג

sam-on ltd - anastrozole 1 mg - film coated tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

אנסטרוזול מדיטק 1 מ"ג ישראל - עברית - Ministry of Health

אנסטרוזול מדיטק 1 מ"ג

sam-on ltd - anastrozole 1 mg - film coated tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.